LONDON – Oxford BioDynamics PLC (LON:), a clinical diagnostics company specializing in precision medicine, has announced a retail offering to raise up to £500,000 through a new share issue. This offer is exclusive to existing eligible shareholders in the United States Kingdom (TADAWUL:) and is conducted through the Winterflood Retail Access Platform (WRAP).
The offer is for up to 100,000,000 new ordinary shares at an issue price of 0.5 pence each. The issue price represents a 44% discount to the median closing price of 0.9p per ordinary share on Sunday. The funds raised will be used in the same way as the proceeds of a concurrent placement and subscriptions aimed at raising a minimum of £6 million.
The retail offering is part of the company’s broader fundraising strategy, which is conditional on shareholder approval at a general meeting scheduled for January 31, 2025 and admission subsequent date of the new shares for trading on the AIM market of London Stock Exchange (LON:). Negotiations are expected to begin on February 4, 2025.
Oxford BioDynamics is targeting its retail shareholder base in the UK, providing them with the opportunity to participate in the growth of the business. The minimum subscription per investor is set at £250, with the offer expected to close at 4.30pm on Thursday this week. Shareholders interested in participating can contact their brokers or asset managers.
The new ordinary shares issued will be fully paid and will rank pari passu with existing ordinary shares, including the right to receive dividends and other distributions declared after the date of issue.
Investors are reminded that investing in the company involves risks and capital is involved. The value of investments may fluctuate, which may cause investors to receive less than their original investment.
This announcement is based on a press release and does not constitute an offer or solicitation in any jurisdiction where such actions would violate applicable laws. The Offer is not being made in the United States, Australia, Canada, New Zealand, Japan, South Africa, any member state of the EEA or any jurisdiction where it would be illegal. The shares offered at retail will not be registered under the US Securities Act and are not offered in the United States.
The information provided in this article is for informational purposes and does not purport to be complete or complete. It is based on a press release and should be read in conjunction with the company’s full announcement for a complete understanding of the terms and conditions of the offering.
This article was generated with the support of AI and reviewed by an editor. For more information, consult our General Terms and Conditions.
